 | • レポートコード：D0GIR-01546 • 出版社/出版日：GlobalInfoResearch / 2020年9月23日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール • 産業分類：医療、製薬、バイオ |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、非アルコール性脂肪性肝疾患治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。非アルコール性脂肪性肝疾患治療の種類別市場規模（抗酸化剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体アゴニスト、その他）、用途別市場規模（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、AstraZeneca、Cardax、Roche、Gilead Sciences、Daewoong、GW Pharmaceuticals、Novartis、Merck、Limerick BioPharma、Allergan、Takeda Pharmaceutical ・地域別グローバル市場分析 2015年-2020年 ・非アルコール性脂肪性肝疾患治療の北米市場（アメリカ、カナダ、メキシコ） ・非アルコール性脂肪性肝疾患治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・非アルコール性脂肪性肝疾患治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・非アルコール性脂肪性肝疾患治療の南米市場（ブラジル、アルゼンチン） ・非アルコール性脂肪性肝疾患治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：抗酸化剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体アゴニスト、その他 ・用途別分析：病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Non Alcoholic Fatty Liver Disease Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Non Alcoholic Fatty Liver Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Non Alcoholic Fatty Liver Disease Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Non Alcoholic Fatty Liver Disease Treatment market has been segmented into:
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
By Application, Non Alcoholic Fatty Liver Disease Treatment has been segmented into:
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Non Alcoholic Fatty Liver Disease Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Non Alcoholic Fatty Liver Disease Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Non Alcoholic Fatty Liver Disease Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Non Alcoholic Fatty Liver Disease Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Non Alcoholic Fatty Liver Disease Treatment Market Share Analysis
Non Alcoholic Fatty Liver Disease Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Non Alcoholic Fatty Liver Disease Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Non Alcoholic Fatty Liver Disease Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Non Alcoholic Fatty Liver Disease Treatment are:
Pfizer
AstraZeneca
Cardax
Roche
Gilead Sciences
Daewoong
GW Pharmaceuticals
Novartis
Merck
Limerick BioPharma
Allergan
Takeda Pharmaceutical
Table of Contents
1 Non Alcoholic Fatty Liver Disease Treatment Market Overview
1.1 Product Overview and Scope of Non Alcoholic Fatty Liver Disease Treatment
1.2 Classification of Non Alcoholic Fatty Liver Disease Treatment by Type
1.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type in 2019
1.2.3 Antioxidants
1.2.4 Thiazolidinedione
1.2.5 Biguanides
1.2.6 Lipid lowering Agents
1.2.7 FXR Receptor Agonist
1.2.8 Others
1.3 Global Non Alcoholic Fatty Liver Disease Treatment Market by Application
1.3.1 Overview: Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Drug Stores
1.3.5 Online Pharmacy
1.3.6 Others
1.4 Global Non Alcoholic Fatty Liver Disease Treatment Market by Regions
1.4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Non Alcoholic Fatty Liver Disease Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Non Alcoholic Fatty Liver Disease Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Non Alcoholic Fatty Liver Disease Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non Alcoholic Fatty Liver Disease Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Non Alcoholic Fatty Liver Disease Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non Alcoholic Fatty Liver Disease Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 AstraZeneca
2.2.1 AstraZeneca Details
2.2.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 AstraZeneca SWOT Analysis
2.2.4 AstraZeneca Product and Services
2.2.5 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Cardax
2.3.1 Cardax Details
2.3.2 Cardax Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Cardax SWOT Analysis
2.3.4 Cardax Product and Services
2.3.5 Cardax Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Roche SWOT Analysis
2.4.4 Roche Product and Services
2.4.5 Roche Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Gilead Sciences
2.5.1 Gilead Sciences Details
2.5.2 Gilead Sciences Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Gilead Sciences SWOT Analysis
2.5.4 Gilead Sciences Product and Services
2.5.5 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Daewoong
2.6.1 Daewoong Details
2.6.2 Daewoong Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Daewoong SWOT Analysis
2.6.4 Daewoong Product and Services
2.6.5 Daewoong Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 GW Pharmaceuticals
2.7.1 GW Pharmaceuticals Details
2.7.2 GW Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 GW Pharmaceuticals SWOT Analysis
2.7.4 GW Pharmaceuticals Product and Services
2.7.5 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Novartis SWOT Analysis
2.8.4 Novartis Product and Services
2.8.5 Novartis Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 Merck
2.9.1 Merck Details
2.9.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Merck SWOT Analysis
2.9.4 Merck Product and Services
2.9.5 Merck Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 Limerick BioPharma
2.10.1 Limerick BioPharma Details
2.10.2 Limerick BioPharma Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Limerick BioPharma SWOT Analysis
2.10.4 Limerick BioPharma Product and Services
2.10.5 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.11 Allergan
2.11.1 Allergan Details
2.11.2 Allergan Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Allergan SWOT Analysis
2.11.4 Allergan Product and Services
2.11.5 Allergan Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.12 Takeda Pharmaceutical
2.12.1 Takeda Pharmaceutical Details
2.12.2 Takeda Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Takeda Pharmaceutical SWOT Analysis
2.12.4 Takeda Pharmaceutical Product and Services
2.12.5 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Non Alcoholic Fatty Liver Disease Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Non Alcoholic Fatty Liver Disease Treatment Players Market Share
3.2.2 Top 10 Non Alcoholic Fatty Liver Disease Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Non Alcoholic Fatty Liver Disease Treatment Revenue and Market Share by Regions
4.2 North America Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
5 North America Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries
5.1 North America Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
5.2 USA Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
6 Europe Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries
6.1 Europe Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
6.2 Germany Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
6.4 France Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries
7.1 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
7.2 China Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
7.5 India Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
8 South America Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries
8.1 South America Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
8.2 Brazil Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Non Alcoholic Fatty Liver Disease Treatment by Countries
9.1 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Non Alcoholic Fatty Liver Disease Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Forecast by Type (2019-2024)
10.3 Antioxidants Revenue Growth Rate (2015-2025)
10.4 Thiazolidinedione Revenue Growth Rate (2015-2025)
10.5 Biguanides Revenue Growth Rate (2015-2025)
10.6 Lipid lowering Agents Revenue Growth Rate (2015-2025)
10.7 FXR Receptor Agonist Revenue Growth Rate (2015-2025)
10.8 Others Revenue Growth Rate (2015-2025)
11 Global Non Alcoholic Fatty Liver Disease Treatment Market Segment by Application
11.1 Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application (2015-2020)
11.2 Non Alcoholic Fatty Liver Disease Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Pharmacy Revenue Growth (2015-2020)
11.4 Retail Pharmacy Revenue Growth (2015-2020)
11.5 Drug Stores Revenue Growth (2015-2020)
11.6 Online Pharmacy Revenue Growth (2015-2020)
11.7 Others Revenue Growth (2015-2020)
12 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2021-2025)
12.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2021-2025)
12.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Forecast by Regions (2021-2025)
12.3 North America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
12.6 South America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Non Alcoholic Fatty Liver Disease Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 7. Pfizer Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 10. Pfizer Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. AstraZeneca Corporate Information, Location and Competitors
Table 12. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 13. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2018-2019)
Table 14. AstraZeneca SWOT Analysis
Table 15. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 16. AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Cardax Corporate Information, Location and Competitors
Table 18. Cardax Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 19. Cardax Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Cardax SWOT Analysis
Table 21. Cardax Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 22. Cardax Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Roche Corporate Information, Location and Competitors
Table 24. Roche Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 25. Roche Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Roche SWOT Analysis
Table 27. Roche Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 28. Roche Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Gilead Sciences Corporate Information, Location and Competitors
Table 30. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 31. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Gilead Sciences SWOT Analysis
Table 33. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 34. Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Daewoong Corporate Information, Location and Competitors
Table 36. Daewoong Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 37. Daewoong Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Daewoong SWOT Analysis
Table 39. Daewoong Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 40. Daewoong Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. GW Pharmaceuticals Corporate Information, Location and Competitors
Table 42. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 43. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 44. GW Pharmaceuticals SWOT Analysis
Table 45. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 46. GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Novartis Corporate Information, Location and Competitors
Table 48. Novartis Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 49. Novartis Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Novartis SWOT Analysis
Table 51. Novartis Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 52. Novartis Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Merck Corporate Information, Location and Competitors
Table 54. Merck Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 55. Merck Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 56. Merck SWOT Analysis
Table 57. Merck Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 58. Merck Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Limerick BioPharma Corporate Information, Location and Competitors
Table 60. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 61. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 62. Limerick BioPharma SWOT Analysis
Table 63. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 64. Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Allergan Corporate Information, Location and Competitors
Table 66. Allergan Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 67. Allergan Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 68. Allergan SWOT Analysis
Table 69. Allergan Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 70. Allergan Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Takeda Pharmaceutical Corporate Information, Location and Competitors
Table 72. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Major Business
Table 73. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Total Revenue (USD Million) (2017-2018)
Table 74. Takeda Pharmaceutical SWOT Analysis
Table 75. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Product and Solutions
Table 76. Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) by Players (2015-2020)
Table 78. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Players (2015-2020)
Table 79. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) by Regions (2015-2020)
Table 80. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Regions (2015-2020)
Table 81. North America Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
Table 82. North America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Table 83. Europe Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) by Countries (2015-2020)
Table 84. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) by Countries (2015-2020)
Table 85. South America Non Alcoholic Fatty Liver Disease Treatment Revenue by Countries (2015-2020)
Table 86. South America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Table 87. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) by Countries (2015-2020)
Table 88. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Table 89. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) by Type (2015-2020)
Table 90. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Type (2015-2020)
Table 91. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Forecast by Type (2021-2025)
Table 92. Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Application (2015-2020)
Table 93. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Application (2015-2020)
Table 94. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Forecast by Application (2021-2025)
Table 95. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Non Alcoholic Fatty Liver Disease Treatment Picture
Figure 2. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type in 2019
Figure 3. Antioxidants Picture
Figure 4. Thiazolidinedione Picture
Figure 5. Biguanides Picture
Figure 6. Lipid lowering Agents Picture
Figure 7. FXR Receptor Agonist Picture
Figure 8. Others Picture
Figure 9. Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application in 2019
Figure 10. Hospital Pharmacy Picture
Figure 11. Retail Pharmacy Picture
Figure 12. Drug Stores Picture
Figure 13. Online Pharmacy Picture
Figure 14. Others Picture
Figure 15. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 16. North America Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Europe Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. South America Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 22. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share in 2019
Figure 24. Global Top 10 Players Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share in 2019
Figure 25. Key Players Market Share Trend
Figure 26. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 27. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Regions (2015-2020)
Figure 28. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Regions in 2018
Figure 29. North America Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Europe Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 31. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 32. South America Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 33. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 34. North America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Figure 35. North America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries in 2019
Figure 36. USA Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 37. Canada Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 38. Mexico Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 39. Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Figure 40. Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries in 2019
Figure 41. Germany Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 42. UK Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 43. France Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 44. Russia Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 45. Italy Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Figure 47. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries in 2019
Figure 48. China Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Japan Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 50. Korea Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 51. India Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 52. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 53. South America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Figure 54. South America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries in 2019
Figure 55. Brazil Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 56. Argentina Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 57. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries (2015-2020)
Figure 58. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Countries in 2019
Figure 59. Saudi Arabia Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 60. UAE Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 61. Egypt Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 62. South Africa Non Alcoholic Fatty Liver Disease Treatment Revenue and Growth Rate (2015-2020)
Figure 63. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Type (2015-2020)
Figure 64. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Type in 2019
Figure 65. Global Non Alcoholic Fatty Liver Disease Treatment Market Share Forecast by Type (2021-2025)
Figure 66. Global Antioxidants Revenue Growth Rate (2015-2020)
Figure 67. Global Thiazolidinedione Revenue Growth Rate (2015-2020)
Figure 68. Global Biguanides Revenue Growth Rate (2015-2020)
Figure 69. Global Lipid lowering Agents Revenue Growth Rate (2015-2020)
Figure 70. Global FXR Receptor Agonist Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Application (2015-2020)
Figure 73. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Share by Application in 2019
Figure 74. Global Non Alcoholic Fatty Liver Disease Treatment Market Share Forecast by Application (2021-2025)
Figure 75. Global Hospital Pharmacy Revenue Growth Rate (2015-2020)
Figure 76. Global Retail Pharmacy Revenue Growth Rate (2015-2020)
Figure 77. Global Drug Stores Revenue Growth Rate (2015-2020)
Figure 78. Global Online Pharmacy Revenue Growth Rate (2015-2020)
Figure 79. Global Others Revenue Growth Rate (2015-2020)
Figure 80. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 81. Global Non Alcoholic Fatty Liver Disease Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 82. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 83. North America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
Figure 84. Europe Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
Figure 85. Asia-Pacific Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
Figure 86. South America Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
Figure 87. Middle East and Africa Non Alcoholic Fatty Liver Disease Treatment Revenue Market Forecast (2021-2025)
Figure 88. Sales Channel: Direct Channel vs Indirect Channel
脂肪肝治療の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Fatty Liver Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Fatty Liver Treatment m…- 肝疾患診断の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Liver Disease Diagnostics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimizat…
- 非アルコール性脂肪性肝炎（NASH）バイオマーカーの世界市場2020年：メーカー別、地域別、種類・用途別 Market Overview The Non-alcoholic Steatohepatitis (NASH) Biomarkers market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players,…
- ニューカッスル病治療薬の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The global Newcastle Disease Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Newcastle Disease…
- 肝機能検査の世界市場2020年：企業別、地域別、種類・用途別 Market Overview The Liver Function Tests market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, …